Business Context and Reporting Period
Company: Silexion Therapeutics Corp (SLXN)
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2025
Reporting Period: Single event date (November 25, 2025)
Business Overview: Silexion Therapeutics is an emerging growth company incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel. The company develops next-generation RNA silencing therapies.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain audited or unaudited financial statements.
- Revenue: Not provided in this filing.
- Profit/Loss: Not provided in this filing.
- Cash Flow: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
- Securities Registered: Ordinary Shares (SLXN) and Warrants (SLXNW) on The Nasdaq Stock Market LLC.
Material Changes
The filing reports a material non-financial event under Item 7.01 (Regulation FD Disclosure):
- Event: Successful completion of toxicology studies for the company's lead candidate, SIL204.
- Significance: The studies were completed ahead of the planned Phase 2/3 clinical trial for pancreatic cancer.
- Comparison: No prior comparable period data is included in this specific 8-K filing.
Guidance, Outlook, and Risks
Management Commentary: The press release incorporated by reference highlights the advancement of SIL204, a next-generation RNA silencing therapy, positioning the company to proceed toward Phase 2/3 clinical trials in pancreatic cancer.
Outlook: The completion of toxicology studies is a prerequisite for advancing to the next clinical phase, suggesting a positive near-term operational outlook for the SIL204 program.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical development. The information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the toxicology study results and the timeline for the Phase 2/3 trial initiation.
- Review the company's most recent 10-K or 10-Q filings for current cash runway, as this 8-K does not provide liquidity data.
- Monitor upcoming regulatory filings for the Investigational New Drug (IND) application status related to the Phase 2/3 trial.
- Confirm the exercise price and terms of the outstanding warrants (SLXNW) listed at $1,552.50 per share.